---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-261661"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2026-06-08T20:01:29+00:00"
generated_at: "2026-06-08T20:07:20.649636+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# RemeGen gets NMPA nods for telitacicept in IgAN and Sjögren’s; Vor Bio holds ex-China rights

## Summary
- First BAFF/APRIL-targeting therapy approved for IgA nephropathy; conditional NMPA approval based on Phase 3 TELIGAN trial showing 55% placebo-adjusted UPCR reduction.
- First regulatory approval ever for Sjögren’s disease in China; Phase 3 met primary and secondary endpoints (ESSDAI, ESSPRI).
- Telitacicept now has five approved indications in China; Vor Bio holds exclusive development/commercialization rights outside Greater China.
- Phase 3 IgAN results recently published in NEJM; eGFR stable at 39 weeks vs declines on placebo.
- Vor Bio CEO cites milestone validating dual BAFF/APRIL inhibition as potential foundational therapy for autoimmune diseases.

## SEC filing metadata
- accession: 0001193125-26-261661
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2026-06-08T20:01:29+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312526261661/0001193125-26-261661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312526261661/vor-20260608.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-261661
- JSON: https://secwatch.observer/filing/0001193125-26-261661.json
- Plain text: https://secwatch.observer/filing/0001193125-26-261661.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.